Sequentia Biotech S.L.. (9/27/24). "Press Release: Sequentia Biotech Secures €10 Million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications". Barcelona.

	Organisation	EIC Fund (European Innovation Council Fund)
	Group	EU (govt)
	Organisation 2	Seventure Partners
	Group	BPCE (Group)
	Product	venture capital
	Person	de Crémoux, Isabelle (BPCE 201110– CEO of Seventure Partners)

Sequentia Biotech, a deeptech and leading bioinformatics company focused on the a108445nalysis and application of omics data, announces a €10million Series A, led by Seventure Partners, a French Venture Capital & Growth investment company with an extensive experience in Life Sciences. The Series A is co-invested by the EIC Fund, the European Commission initiative dedicated to accelerating innovative start-ups across the European Union.

The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of #omics – the collective characterization and quantification of pools of biological molecules that translate into the structure function and dynamics of an organism(s). Examples of omics include genomics, transcriptomics, epigenomics and microbiomics. The application of omics is driving the development of more precise diagnostic tools in the fields of biomedicine, agritech (e.g. crop protection and nutrition) and in the food industry (e.g. improving food production and quality).

The funds will enable Sequentia Biotech to accelerate the market introduction and expansion of its flagship platform, MICK, and the scale up of its Best-in-Class Bioinformatics Enabling Technologies, driving its ambitious go-to-market strategy. The MICK platform provides state of the art data analysis and interpretation, enabling a deeper exploration of microbiome data and translating it into actionable insights for multiple applications. It has the potential to redefine clinical decision-making, by integrating bioinformatics intelligence around omics into medical practice, biomedical and biopharma applications.

Walter Sanseverino, CEO and Co-Founder at Sequentia Biotech, welcomed the funding stating, “We are delighted to announce this fundraising and our backing by Seventure Partners and the EIC Fund, two highly renowned venture capital investors with strong track records in supporting innovative companies in the life sciences sector. This investment will play a major role in advancing our mission to unlock the full potential of omics and accelerate the adoption of MICK by researchers and healthcare professionals globally.”

“We believe, we are on the brink of a new era in omics research and in our view, this investment is a signal of the market’s confidence in our vision and MICK‘s potential to disrupt the status quo,” said Riccardo Aiese Cigliano, Scientific Director and Co-Founder at Sequentia Biotech. “Our MICK platform offers a major step forward across multiple health applications, from precision nutrition and wellness, to understanding biological processes and diseases, to creating microbiome-based treatments and therapies.

Isabelle de Cremoux, CEO & managing partner of Seventure Partners, commented on the investment, saying, “Sequentia Biotech’s aim to use MICK platform to democratise the development and use of precision multi-omics resonates with our commitment to invest in companies at the forefront of scientific and technological innovation. We believe Sequentia Biotech has the potential to make a significant impact, and we look forward to supporting the management team as it navigates the next phase of the Company’s development.”

The European Commission’s EIC Fund is committed to identifying and supporting high-impact scale-ups that can create technological breakthroughs, while also driving job creation and economic advancement. “Our investment in Sequentia Biotech is aligned with our goal to propel Europe’s most innovative companies to the forefront of global technology and industry leadership,” said Svetoslava Georgieva, Chair of the EIC Fund Board. “The EIC Fund is excited to back Sequentia Biotech, a move that reinforces Europe’s position at the cutting edge of microbiome analysis and precision medicine on the global stage.”

Walter Sanseverino, CEO of Sequentia Biotech, commented, “This investment not only fuels our growth but also reinforces our resolve to foster innovation and economic growth within the EU and beyond.”

Notes to Editors

About Sequentia Biotech:

Sequentia Biotech, a pioneering bioinformatics firm established in 2013, specialises in cutting-edge technological solutions across the biomedical, agro-industrial and research domains. With 15 years of experience and significant investments in R&D, the company has successfully completed over 800 bioinformatics projects, served clients in 63 countries – including MNEs, top research institutions, hospitals and public authorities and contributed to over 70 publications with a H-index of 130.

Our vision is to advance precision medicine and agro-industrial innovation by harnessing the power of multi-omics sciences, addressing humanity’s greatest challenges with our pioneering bioinformatics enabling solutions.

About Seventure Partners

Seventure Partners is a long-term equity investor who actively supports innovative companies aiming at generating positive impacts on People, Society, Sustainability and the Planet.

With ~€1b net commitments under management as of the end of 2023, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in two main fields: (i) Life Sciences (biotechnology, health & digital health, nutrition, #foodtech, blue economy, aquaculture, animal feed, agriculture, sport & wellness…) with a particular focus on the microbiome, across Europe, Israel, Asia, Australia and North America, and (ii) Digital Technologies (fintech, retailtech, cybersecurity, etc.) in Europe, mainly France and Germany.

Seventure’s investments can range between €500k and €10m per round, or up to €20m per company, to support the development of companies from creation (seed and first round) to development capital financing rounds (venture, growth, pre-IPO and IPO).

In the field of Life Sciences, Seventure invests mainly in “classic” approaches, such as drugs, medical devices and diagnostics, and industrial biotechnology, as well as “beyond the pill” approaches, such as digital health, preventive medicine, well-being, personalised medicine, nutrition and food, with a particular interest in the applications of discoveries related to the microbiome and foodtech.

With Health for Life Capital™ funds I, II (€160m and €250m) and its co-investments funds, Seventure is a worldwide leader in microbiome investments with more than 30 companies in its portfolio to date.

The Health for Life Capital™ funds have attracted strategic investments from prestigious organisations including Danone, Novartis, two US-based global food ingredient providers (to be disclosed), Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions, family offices and entrepreneurs.

For more details: http://www.seventure.fr/en X: @seventurep

Seventure publishes every year a global review of the scientific progress in the microbiome. To get a free copy of the January 2024 report, please send your request to contact@seventure.fr

About EIC Fund:

The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as investment adviser to the EIC Fund.

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

#Biotech #AI #Microbiome#Deeptech#Precision Medicine #healthforlifecapital™

For more information about Sequentia Biotech and this investment, please contact:

Press contacts

SEQUENTIA BIOTECH

Walter Sanseverino
Sequentia Biotech
CEO & Co-Founder
Tel +34 930 10 73 68
wsanseverino@sequentiabiotech.com

SEVENTURE PARTNERS

Agence Yucatan
Caroline Prince
Tel : + 33 1 53 63 27 35 /
+ 33 6 07 55 90 06
cprince@yucatan.fr

Seventure Partners
Isabelle de Cremoux, CEO & managing partner
Tel : + 33 1 57 95 03 77
isabelle.decremoux@seventure.fr

Record changed: 2024-10-01